RxDoctor Payments Data

David Stockman, MD

Dermatopathology · Saginaw, MINPI 1407086424

Payments from drug & device makers

What this record shows

This record is dominated by other: $21,456 of the $23,565 with a category attached, or 91.1%. Biofrontera Inc. accounts for 91.5% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2024 at $22,064 and has fallen 99.2% since, to $174 in 2025. Among dermatopathology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$23,565in general payments, 2019–2025

Across 151 payments — averaging $156.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biofrontera Inc.$22K
  • Novartis$660
  • Pfizer$269
  • Boehringer Ingelheim$164
  • Myriad Genetic Laboratories, Inc.$148
  • Regeneron Healthcare Solutions, Inc.$86
  • plus $681 from 20 others

What the payments were for

  • Food & beverage$2,1099%
  • Other$21,45691%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,565 in reported general payments places this provider in the 95th percentile of 28 dermatopathology providers in Michigan.

See all dermatopathology providers in Michigan

Medicare billing

Part B allowed, 2024
$572,066
Medicare patients
751
Services billed
6,416

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cosentyx Sensoready (2 Pens)Secukinumab18$234,571
Humira PenAdalimumab11$140,669
Dupixent PenDupilumab16$61,874
Betamethasone Valerate118$4,257
Halobetasol Propionate37$2,418
Calcipotriene12$2,335
Clobetasol Propionate58$2,148
Ketoconazole121$1,808
Clindamycin Phosphate38$938
Doxycycline Monohydrate34$592
Hydroxychloroquine Sulfate24$575
MethotrexateMethotrexate Sodium26$467
Leflunomide11$408
Betamethasone Dipropionate12$383
Spironolactone46$372

Paid to pharmacies, not to this prescriber.

Other dermatopathology in Saginaw

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →